Old Toxicities: Pneumonitis Related to Palbociclib - A Case Report

Old Toxicities: Pneumonitis Related to Palbociclib - A Case Report

Data de publicació online: 01/10/2020 Data de publicació en paper: 1 Octubre 2020 Revista: Breast Care

Abstract:

Background
Palbociclib is a specific inhibitor of cyclin-dependent kinases 4 and 6 that is approved for the treatment of advanced or metastatic breast cancer patients. Despite a good toxicity profile in pivotal trials, where asymptomatic neutropenia was the main adverse effect, its wider use in clinical practice may show less prevalent but serious toxicities.

Case presentation
Here, we describe a case of pneumonitis due to palbocicblib. A 57-year-old female with breast cancer with bone metastasis presented dyspnea at rest 3 months after beginning treatment with palbociclib and letrozole. Palbociclib-induced pneumonitis was considered the most probable cause after ruling out all alternatives, and the patient was successfully treated with steroids and showed complete remission.

Conclusions
In summary, we present a well-documented case report of pneumonitis related to palbociclib. However, the mechanism of toxicity is still unknown, and there are as yet no reliable biomarkers to predict toxicity with cyclin-dependent kinase 4/6 inhibitors. In this case report, we alert physicians about new drugs that can provoke old toxicities.

Keywords
Case report; Drug-related pneumonitis; Lung toxicity; Palbociclib; Pneumonitis.

Autors: Felip E, Llobera L, Perez-Mañá C, Quintela D, Guasch I, Margelí M, Teruel I, Cirauqui B, Centeno C, Romeo M, Ballana E, Quiroga V

Subscriu-te a la newsletter

Back to Top
Irsi Caixa

Impulsat per:

Fundació 'La Caixa' Generalitat de Catalunya - Departament de Salut

 

HR Excellence in Research

Membre de:

Cerca

Amb la col·laboració de: